News

Catabasis Pharmaceuticals announced that it will present data on CAT-5571, its investigational oral treatment for cystic fibrosis (CF). The drug has potential effectiveness both on improving the working of the cystic fibrosis transmembrane conductance regulator (CFTR), and in treating Pseudomonas aeruginosa infection. The data will be presented at the 30th Annual North American Cystic Fibrosis…

Results of the safety, stability, and effectiveness of Spyryx Biosciences‘ drug candidate SPX-101 for cystic fibrosis (CF) will be presented at the North American Cystic Fibrosis Conference (NACFC) Thursday through Saturday in Orlando, Florida. SPX-101 mimics the function of the protein SPLUNC1, which plays an important role in controlling airway…

A recent study has shown that sputum and throat swabs of adult cystic fibrosis (CF) patients can be used to identify Pseudomonas aeruginosa and Staphylococcus aureus lung infections. CF patients frequently suffer from chronic respiratory infections and inflammation, which ultimately can lead to respiratory failure, the major cause of morbidity and…

The 30th Annual North American Cystic Fibrosis Conference (NACFC), a three-day collaborative forum to help advance cystic fibrosis (CF) understanding, treatment and research, opens on Thursday, Oct. 27, at the Orange County Convention Center in Orlando, Florida. NACFC also provides participants access to continuing medical education, and the…

A new device using Bluetooth technology, called eRapid, can administer inhaled therapies to patients with cystic fibrosis (CF) and alert doctors that patients have taken their medicine, improving their adherence to treatments. The findings come from a study conducted by researchers at Ventura County Medical Center in California. The study,…

Corbus Pharmaceuticals announced that the European Medicines Agency (EMA) has designated the company’s synthetic oral endocannabinoid-mimetic, Resunab (JBT-101), an orphan drug as a potential treatment for people with cystic fibrosis (CF). Resunab, which is currently being evaluated in a Phase 2 clinical trial in CF patients, preferentially binds to the CB2 receptor…

Good Start Genetics  has announced the launch of VeriYou, its new saliva-based screening test for cystic fibrosis (CF) and spinal muscular atrophy (SMA), two common inherited genetic diseases. The screening kit is available for order on the company’s website, for a cost of about $150, and results —…

Researchers at the Perelman School of Medicine at the University of Pennsylvania, Cincinnati Children’s Hospital and Boston University have been awarded a $5.2 million grant, running for seven years, for collaborative work to explore mechanisms of lung regeneration in diseases such as cystic fibrosis. The grant, one…

The U.S. Food and Drug Administration (FDA) approved a new dose of Pertzye (pancrelipase) to specifically treat infants (up to one year of age) with exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) or other conditions. The approval refers to a new capsule containing 4,000 USP units of lipase…

The National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has granted a five-year, $13.3 million award to Benjamin Gaston, MD, to lead a research program aimed at translating new, small molecule drugs into personalized combination therapies for children with severe asthma and cystic fibrosis (CF). The…